Results 91 to 100 of about 28,276 (143)

Functional status as a predictor of loss to follow-up among people living with HIV on antiretroviral therapy in Tangerang District, Indonesia. [PDF]

BMC Infect Dis
Lugito NPH, Simanjuntak MI, Sumantri S, Kho Y, Kosayuz S, Liauw R.   +5 more
europepmc   +1 more source

Switch to Fixed Dose of Doravirine, Lamivudine, Tenofovir Disoproxil Fumarate Versus Bictegravir, Emtricitabine, and Tenofovir Alafenamide Fumarate in Virologically Suppressed Adults on Efavirenz-Based Regimens: 48-Week Results of a Real-world, Prospective, Observational Cohort Study. [PDF]

Open Forum Infect Dis
Li A, Li Z, Li J, Gao Y, Dai L, Liu A, Zhang H, Wang X, Wu L, Yao Y, Liu L, Ye J, Sun L.   +12 more
europepmc   +1 more source

Special Issue: Polymers, Polymer Blends, and Polymeric Drug Release Systems with Antiviral or Antibacterial Effect-2nd Edition. [PDF]

Int J Mol Sci
Dobrzyński P.
europepmc   +1 more source

Lamivudine resistance in untreated chronic hepatitis B patients in Turkey

The Turkish Journal of Gastroenterology, 2008
Semra TUNÇBİLEK, Şükran KÖSE, Ahmet ELALDI, Sezin AKMAN   +3 more
doaj  

Assessing the preparedness of primary healthcare facilities for the implementation of universal test and treat in uThukela District, South Africa: a cross-sectional study. [PDF]

BMJ Public Health
Turawa E, Basera W, Hlongwa M, Mathole T, Bradshaw D, Nicol E.   +5 more
europepmc   +1 more source

Long-Term Outcomes of Patients Who Receive a Liver Transplant for Hepatitis B With Limited Use of Hepatitis B Immunoglobulin. [PDF]

Clin Transplant
Roldan GA, Loon E, Lake J, Lim N.
europepmc   +1 more source

Lamivudine and tenofovir pharmacokinetic variability in people with HIV in Papua New Guinea. [PDF]

Br J Clin Pharmacol
Andriguetti NB, Barratt DT, Tucci J, Pumuye P, Somogyi AA.   +4 more
europepmc   +1 more source

Prevalence and correlates of hyperbilirubinemia among people living with HIV (PLHIV) receiving atazanavir boosted with ritonavir (ATV/r). [PDF]

BMC Gastroenterol
Farrokhi H, Shahmohamadi E, Pashaei A, Emadi Koochak H, Nooralioghli Parikhani S, Fathi Amrollah M, Mirzapour P, Dehghan Manshadi SA, SeyedAlinaghi S, Hackett D.   +9 more
europepmc   +1 more source

No changes in weight, body composition or metabolic parameters after the switch to dolutegravir and lamivudine compared to continued treatment with dolutegravir, abacavir and lamivudine for virologically suppressed HIV infection (The AVERTAS trial). [PDF]

BMC Infect Dis
Heje KB, Lindhardt MS, Meddis A, Knudsen A, Kronborg G, Weis N, Lebech AM, Kirk O, Helweg-Larsen J, Helms M, Fischer CP, Hansen AE, Møller S, Siebner HR, Hove JD, Gerstoft J, Benfield T.   +16 more
europepmc   +1 more source

Sustained HIV Suppression With Co-formulated Tenofovir Disoproxil Fumarate/Lamivudine/Dolutegravir in a Person With Transmitted Dolutegravir Resistance and Pretreatment Resistance to Lamivudine: a Case Report From HPTN 083. [PDF]

Open Forum Infect Dis
Moore HP, Fogel JM, Marzinke MA, Halvas EK, Parikh UM, Mellors JW, Penrose KJ, Seisa M, Petropoulos C, Price AL, Moser A, Wang Z, McCauley M, Valencia-Huamaní J, Rinehart AR, Rooney JF, Soto-Torres L, Grinsztejn B, Landovitz RJ, Eshleman SH.   +19 more
europepmc   +1 more source